Related Experiment Video
Updated: May 24, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Pharmacy effect on adherence to antidiabetic medications.
Krishna P Sharma1, Thomas N Taylor
1Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA. ksharma@wayne.edu
Medical Care
|February 23, 2012
Summary
Pharmacy type significantly impacts patient medication adherence, independent of patient characteristics. This highlights the importance of pharmacy services in improving medication adherence for antidiabetic patients.
Area of Science:
- Health Services Research
- Pharmaceutical Sciences
- Patient Adherence Studies
Background:
- Limited research exists on healthcare providers' influence on patient medication adherence.
- Studies often focus on patient characteristics rather than provider-level factors.
Purpose of the Study:
- To evaluate the impact of pharmacy-level factors on medication adherence.
- Specifically assessed the effect on patients using antidiabetic medications.
Main Methods:
- Retrospective, cross-sectional study utilizing insurance claims data.
- Employed multilevel random and mixed-effect models to analyze pharmacy-level effects.
- Medication adherence measured by proportion of days covered (PDC).
Main Results:
- Pharmacy cluster effect was statistically significant, accounting for approximately 12% of adherence variance.
- This effect remained significant even after controlling for covariates.
- Age, sex, mail order pharmacy use, and prescription copay were associated with adherence.
Conclusions:
- Significant variation in medication adherence is attributable to pharmacy factors.
- Pharmacies may influence patient adherence through educational or persuasive efforts.
- Further research is needed to identify specific pharmacy characteristics and practices that enhance adherence.
Related Concept Videos
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...